Medco Offering MolecularMD Companion Dx Test for Tyrosine Kinase Inhibitor Response | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Medco Health Solutions will offer patients diagnosed with chronic myeloid leukemia a companion diagnostic test to assess their response to tyrosine kinase inhibitor, or TKI, therapy under an agreement with MolecularMD announced today.

MolecularMD's qRT-PCR BCR-ABL assay will be used to help physicians make treatment decisions and to monitor patients on TKI therapy, under the terms of the deal.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.